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ABSTRACT
Retinoic acid receptors (RARs) interact, in a ligand-
dependent fashion, with many coregulators that par-
ticipate in a wide spectrum of biological responses,
ranging from embryonic development to cellular
growth control. The transactivating function of
these ligand-inducible transcription factors reside
mainly, but not exclusively, in their ligand-binding
domain(AF2),which recruits or dismiss coregulators
in a ligand-dependent fashion. However, little is
known about AF2-independent function(s) of RARs.
Wehaveisolatedtheproliferatingcellnuclearantigen
(PCNA)asarepressorofRARtranscriptionalactivity,
able to interact with an AF2-crippled RAR. The
N-terminus of PCNA interacts directly with the
DNA-binding domain of RAR, and PCNA is recruited
to a retinoid-regulated promoter in intact cells. This
interaction affects the transcriptional response to
retinoic acid in a promoter-specific manner, confer-
ring an unanticipated role to PCNA in transcrip-
tional regulation. Our findings also suggest a role
for RAR as a factor coordinating DNA transcription
and repair.
INTRODUCTION
The modulation of gene expression by ligand-regulated
nuclear receptors (NRs) is carefully controlled to achieve a
precisespacial andtemporalexpression ofproteinsinvolved in
crucial cellular processes. Several mechanisms leading to such
a restricted expression have been identiﬁed, among which the
availability of the cognate ligand, the tissue-speciﬁc expres-
sion of NRs themselves or of their coregulators have been
documented. These different parameters condition the biolo-
gical responses to a given ligand and, therefore, will affect
major biological processes, such as differentiation, prolifera-
tion or apoptosis.
While elegant studies in yeast have characterized the role of
network of transcription factors in the control of the cell cycle
(1), relatively little is known on how cell cycling affects tran-
scription factors activity. Nevertheless, D-type cyclins, which
regulate the progression through the G1 phase of the cell cycle,
have been shown to interact physically with transcription
factors and to regulate their activities. Notably, cyclin D1
interacts with a number of transcription factors, such as the
general transcription factor TAFII250 (2), STAT3 (3), several
NRs [estrogen receptor (ER), androgen receptor (AR) and
thyroid hormone receptor (TR) (4–6)] and some of their core-
gulators [SRC1/NCoA1, GRIP1/NCoA2, AIB1/NCoA3 and
pCAF; reviewed in (7)]. Similarly, the protein phosphatase
Cdc25B, which activates cyclin-dependent kinases, acts as a
coactivator for several NRs [ER, AR, glucocorticoid receptor
(GR) and progesterone receptor (PR) (8)]. While the interac-
tion of cyclin D1 and of Cdc25B with NRs has a different
outcome on their transcriptional activity, these observations,
however, hint at a regulation of NRs activity during cell cycle
progression. Indeed, responsiveness to glucocorticoids, which
activate GR, is observed in G0 and S phases, but not in the G2
phase (9), and the AR losses its transcriptional activity at the
G1/S transition (10).
Retinoic acid receptors (RARs) belong to the superfamily of
NRs and bind to speciﬁc retinoic acid response elements
(RAREs) as heterodimers with retinoic X receptors (RXRs).
The transcriptional activation of these heterodimers is trig-
gered upon binding of all-trans retinoic acid (atRA) to RAR
[reviewed in (11)]. atRA plays a fundamental role in embry-
onic development and homeostasis of vertebrates through
its ability to directly control the transcription of target genes
involved in the control of proliferation, differentiation and
apoptosis (12). Binding of atRA to RAR induces conforma-
tionalchangesintheligand-bindingdomain(LBD),whichcon-
tains the activating function 2 (AF-2), and notably induces the
repositioning of the C-terminal helix H12 (or AF2-activating
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doi:10.1093/nar/gki745domain), resulting in the creation of a charge clamp required
for coactivator recruitment (13), and subsequent transcrip-
tional activation (14). Among these coactivators are proteins
of the p160 family [steroid receptor coactivators 1, 2 and 3
(SRC-1, 2, 3 or NCoA1, 2, 3)] and CBP/p300, which possess
protein acetyl transferase activity, and secondary coactivators,
such as CARM1 or PRMT1, which harbor protein methyl-
transferase activity (11). These cofactors allow chromatin
modiﬁcation and recruitment of the mediator complex
[TRAP/DRIP (15,16)], which stimulates phosphorylation of
the largest subunit of Pol II by TFIIH (17).
While a detailed understanding of the ligand-dependent
activation of RARs has been achieved by structural and func-
tional studies, little is known about the ligand-independent
regulation of RAR transcriptional activity. Nevertheless, it
has been demonstrated that post-translational modiﬁcations
alter RAR activity independently of ligand (18–20). We there-
fore undertook a two-hybrid screen in yeast using an AF2-
inactivated human RARa (hRARa) as a bait to identify
proteins potentially able to regulate RAR functions in a
ligand-independent manner. Among several proteins, the pro-
liferating cell nuclear antigen (PCNA) was identiﬁed as an
RARa interacting protein.
PCNA is the homolog of the b subunit of the prokaryotic
DNA polymerase and is well known as a processivity factor
of eukaryotic DNA polymerases d and e (21). PCNA is an
essential component of the eukaryotic chromosomal DNA
replisome and clamps onto DNA as a trimeric ring, sliding
along it during replication (22). Further studies have also
demonstrated the interaction of PCNA with multiple proteins
involved in DNA repair (23), cell cycle regulation (24) and
chromatin structure remodeling (25).
In this paper, we describe for the ﬁrst time the physical,
direct interaction of PCNA with RARa. We explored the
functional consequences of this interaction on retinoid-
regulated transcription by cell-based transfection and gene
knockdown experiments.
MATERIALS AND METHODS
Materials
atRA was obtained from Sigma. DNA restriction and
modiﬁcation enzymes were from Promega (Charbonnie `res,
France). Polyethyleneimine (ExGen 500) was from
Euromedex (Souffelweyersheim, France), and Lipofectamine
and Lipofectamine 2000 were from Invitrogen Life Techno-
logies (Carlsbad, CA). [
35S]methionine was purchased from
GE Healthcare (Les Ulis, France).
Plasmids
The yeast expression plasmid pLex12-hRARK244A-K262A
was generated by insertion of the hRARaK244A-K262A
cDNA into the Bgl2/Xba1 sites of pLex12, a LexA DBD
fusion vector. pGL3-DR5tk-Luc, p800tk-Luc (containing
800 bp of the human RARb2 promoter), pGL3tk-Luc, pSG5-
hRXRa, pSG5-hRARa, pSG5-hRARa K244A-K262A,
pSG5-hRARa AF1, pSG5-hRARa AF2, pSG5-hRARD403,
pSG5-hRARb, pSG5-hRARg, pSG5-hVDR and pSG5-
hPPARg were described elsewhere (26–31). pET23-PCNA
and pGEX4T-PCNA were gifts from Z. Jonsson and
K. Kohno, respectively. The pCR3.1-PCNA plasmid was
obtained by TA cloning (TA cloning kit; Invitrogen Life Tech-
nologies). pSG5-hRARa, pET23-PCNA, pCR3.1-PCNA,
pM-PCNA and pGEX4T-PCNA mutants were generated
using the QuickChange Site-Directed Mutagenesis Kit (Strata-
gene). All constructs were checked by automatic sequencing.
Yeast two-hybrid library screen
A HeLa cDNA library (in pACT2 vector; Clontech) was
screened using the L40a yeast strain transformed with the
pLex12-hRARK244A-K262A vector, essentially as described
previously (32).
Cell culture and transfections
HeLa Tet-On cells were cultured as monolayers in DMEM
supplemented with 10% fetal calf serum. Cells were transfec-
ted with expression vectors and reporter vectors when
indicated and were then treated when indicated for 16 h
with10
 6MatRA.Transfections werecarriedoutasdescribed
previously (27). The luciferase assay was performed with the
Bright-Glo Luciferase assay system from Promega, and data
points represent the average of at least three independent
experiments performed with triplicate samples.
GST pull-down experiments
The GST vectors were transformed into the Escherichia coli
strain BL21.
35S-labeled proteins were synthesized using the
Quick T7 TnT kit (Promega). Experiments were carried out
essentially as described previously (27). Resin-bound proteins
were resolved by 10% SDS–PAGE and quantiﬁed with a
Storm 860 PhosphorImager (Molecular Dynamics). At least
three independent experiments were carried out with two
different bacterial extracts.
Coimmunoprecipitation assays
HeLa cells were ﬁrst transfected with the pSG5-hRARa
expression vector, then HeLa and MCF7 cells were treated
for 16 h with 1 mM atRA or left untreated. Cell lysates were
prepared using the lysis buffer (10 mM Tris–EDTA, pH 8.0,
240 mM NaCl and 0.1% NP40) and were ﬁrst incubated for 2h
with equilibrated protein G–Sepharose (preclearing). The pre-
cleared lysate was incubated overnight at 4 C with 2 mgo f
anti-RARa antiserum (sc-551; Santa Cruz Biotechnology) or
non-speciﬁc IgG. Immune complexes were then incubated
with 50 ml of protein G–Sepharose for 2 h at 4 C and
beads were washed three times with lysis buffer. Immunoad-
sorbed proteins were analyzed by western blotting with an
anti-PCNA monoclonal antibody or an anti-RARa antiserum
(sc-56 and sc-551, respectively; Santa Cruz Biotechnology). A
similar protocol was followed to characterize PCNA and its
acetylated forms, using an antiacetylated (epsilon acetylated
lysines) protein antibody (Novus Biologicals, Littletown, CO).
siRNA transfection experiments
Human PCNA siRNAs were provided by Dharmacon. siRNAs
were transfected in HeLa and MCF7 cells with Lipofectamine
2000 according to the manufacturer’s protocol.
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RNA extractions and RT–PCR were carried out as described
previously (33). PCRs were carried out as follows: 94 C for
1min,58 Cfor1minand72 Cfor1min.Thenumberofcycles
was adjusted for each transcript to ensure that ampliﬁcation
was in a linear range. Primers were as follows: GAPDH pri-
mers, 50-CCATCACCATCTTCCAGGAG-30 and 50-CCTG-
CTTCACCACCTTCTTG-30; RARa1 primers, 50-GCCAGG-
CGCTCTGACCACTC-30 and 50-AGCCCTTGCAGCCCTC-
ACAG-30; RARa2 primers, 50-CCACCCCTAATCCCTTC-
CTA-30 and 50-AGCCCTTGCAGCCCTCACAG-30; RARb2
primers, 50-AACGCGAGCGATCCGAGCAG-30 and 50-ATT-
TGTCCTGGCAGACGAAGCA-30; and CRABP2 primers,
50-GTGGAGATCAAACAGGAGGGAG-30 and 50-CATGG-
TCAGGATCAGTTCCCC-30.
DNAandchromatinimmunoprecipitation(ChIP)assays
A total of 5 · 10
6 HeLa cells were transfected as described
above with pGL3-DR5-tk Luc, pSG5-hRARa and pSG5-
hRXRa vectors. Non-transfected P19 cells or transfected
HeLa cells were treated with 1 mM atRA overnight. DNA
immunoprecipitations in HeLa cells, ChIP of the RARb2 pro-
moter in P19 cells and PCR ampliﬁcation of the promoter
region of the gene of interest were carried out as described
previously (30,34).
Statistical analysis
All incubations or assays were performed at least in triplicate.
Measured values were used to calculate mean ± SEM.
Calculations were carried out using Prism software (Graph-
PAD Inc., San Diego, CA).
RESULTS
The N-terminus of PCNA interacts with an AF-2 inactivated
RARa and represses wild-type RAR transcriptional activity.
To investigate novel, AF2-independent function(s) of
RARa, a yeast two-hybrid screen was used to select proteins
able to interact with an AF-2 inactivated hRARa. AF-2 inac-
tivation was obtained by mutating K244 and K262 into
alanine, in order to prevent RARa–helix 12 interaction with
the LBD, and thus to impede coactivator recruitment. The
K244A-K262A (termed RAR2K hereafter) mutant displays
a dramatically decreased transcriptional response to retinoids
(27), heterodimerizes with RXR (28) but is unable to interact
with SRC1 in vitro (32). About 10
6 colonies from a HeLa cell
cDNA library were screened with the RAR2K bait. Two out of
the nineteen positive clones encoded the N-terminal fragment
of PCNA (1–127), which includes the N-terminal domain of
PCNA and half of the interdomain connecting loop [(35) and
Figure 1A]. The secondary screening in yeast conﬁrmed this
interaction, which was not affected in the presence of 1 mM
atRA (Figure 1B). To assess the ability of PCNA to interfere
with RARa transcriptional activity, both proteins were over-
expressed in HeLa cells, and RARa transcriptional activity
was monitored using a chimeric reporter gene whose promoter
is driven by three DR5 RAREs. Full-length PCNA was able to
signiﬁcantly decrease RARa transcriptional activity, as well
as the isolated PCNA N-terminal domain, albeit to a lesser
extent (Figure 1C). In contrast, the isolated PCNA C-terminal
domain (which displays signiﬁcant structural homology with,
but strongly diverges from the N-terminal domain when con-
sidering its amino acid sequence) did not affect RARa tran-
scriptional activity. Moreover, PCNA overexpression did not
affect the luciferase activity of a control reporter gene without
DR5 (tk-Luc), showing that this repression is occurring
through the RAREs.
Although PCNA was isolated with a transcriptionally inact-
ive RARa, this does not exclude a possible interference with
the ligand-dependent coactivator loading onto RARa.W e
explored this possibility by overexpression of the DRIP205
NR1 and NR2 boxes, together or not with PCNA. DRIP205, a
subunit of the DRIP/TRAP complex, interacts directly with
NRs. DRIP205 NR boxes contain two LXXLL sequences
required for NR interaction and exert, when overexpressed,
a dominant negative effect on vitamin D3 receptor (31) and on
RARa (Figure 1D) transcriptional activities. Coexpression of
PCNA could therefore either increase DRIP NR boxes inhib-
itory effect, or have no effect. Preventing coactivator loading
by overexpression of the DRIP NR boxes did not affect PCNA
inhibitory effect (Figure 1D). Overexpression of the mutant
LXXAA motifs, which are unable to interact with NRs, had no
statistically signiﬁcant effect on our system. These results are
thus consistent with the hypothesis that PCNA does not target
AF2 function.
PCNA associates withRARainHeLa cells andinMCF7
cells and is recruited to an atRA-regulated promoter
To investigate whether PCNA participates in RARa transcrip-
tional repression through physical interaction in intact
mammalian cells, we carried out immunoprecipitation assays
with an anti-RARa antibody (Figure 2). Western blot analysis
of the immunoprecipitates from HeLa cells, in which
hRARa has been overexpressed, revealed that the anti-
RARa antibody was able to immunoprecipitate endogenous
PCNA (Figure 2A). Similar experiments were carried out in
MCF7 cells, which express a signiﬁcant amount of endogen-
ous RARa. Endogenous RARa was immunoprecipitated, and
analysis of the immunoprecipitate also showed that RARa
coimmunoprecipitated with PCNA (Figure 2B). Thus, in
both cell lines, atRA could signiﬁcantly increase wtRAR inter-
action with endogenous PCNA, in contrast with results
obtained in yeast.
To study the role of the PCNA–RAR interaction in tran-
scriptional repression, we next determined whether PCNA
could interact with DNA-bound RAR-RXR heterodimers.
We ﬁrst used an in vitro GST pull-down assay in which the
ability of PCNA to interact with DNA-bound heterodimers
was assessed (Figure 2C). hRARa/hRXRa heterodimers
were assembled on DNA [DR5 RARE, (27)], incubated or
not with 1 mM atRA and adsorbed on a GST–PCNA matrix.
Only monomeric RARa could interact with PCNA, whereas
monomeric RXRa was unable to engage such an interaction.
When the PCNA matrix was incubated in the presence of
RXRa and RARa, a slightly increased amount of RXRa
could be detected in the matrix-bound fraction. The PCNA/
RARa/RXRa interaction was increased when heterodimers
were assembled onto the DR5 RARE, and became clearly
inﬂuenced by the ligand. Similar experiments were carried
Nucleic Acids Research, 2005, Vol. 33, No. 13 4313out using a GST–SRC1 matrix as a control. Here again, only
RARa could interact with SRC1 under its monomeric form.
DNA-bound heterodimers recruited efﬁciently SRC1 in the
presence of ligand, demonstrating that our assay reﬂects the
DNA- and ligand-dependent formation of the ternary complex
RXR/RAR/SRC1.
Taken together, these results suggest that PCNA is able
to interact with stable RXR/RAR heterodimers, and that
this DNA-bound conﬁguration confers a ligand dependency
to the interaction.
We then determined whether PCNA is indeed recruited
to DNA-bound RXR/RAR heterodimers in intact cells
(Figure 2D). First, HeLa cells were transfected with the
DR5 tk-Luc reporter gene, RARa and RXRa expression
vectors, and subjected to a DNA immunoprecipitation assay
to assess for the interaction of RARa, PCNA and SRC1 on the
chimeric atRA-regulated promoter. RARa was recruited to
the promoter, irrespective of the presence of atRA, in agree-
ment with previous results, and SRC1 was recruited in a
ligand-dependent manner. The PCNA recruitment proﬁle
was very similar to that of SRC1, with a barely detectable
interaction in the absence of ligand, which was signiﬁcantly
increased upon atRA treatment of target cells. P19 cells are
highly sensitive to retinoids and the RARb2 promoter is in this
cell line highly responsive to atRA treatment. Moreover, they
express a high amount of RARa, allowing an efﬁcient immun-
oprecipitationofRARa-associated chromatin,in opposition to
HeLa cells. ChIP assays were therefore carried out to assess
for the presence of PCNA on the promoter of this retinoid-
regulated gene. As shown in Figure 2D (right panel), RARa
was recruited to the RARb2 promoter in a ligand-independent
manner. PCNA was also recruited to the promoter, and again
atRA treatment increased the interaction of PCNA with this
promoter,thuspresumablywithRARa.ThecoactivatorSRC1,
in sharp contrast, was recruited in a ligand-independent man-
ner, an unexpected behavior which is probably related to the
speciﬁc chromatin organization of this promoter (S. Flajollet
and B. Lefebvre, personal communication). Indeed, our
Figure 1. Ayeasttwo-hybridscreenidentifyPCNAasapartnerofhumanRARa.(A)MainfeaturesofthePCNAmolecule.DomainsofPCNAandsomeofitsmost
prominent partners are indicated. (B) The AF2-inactivated RAR mutant (RAR2K) interacts with PCNA in a ligand-independent manner. Yeasts were transformed
with various pLex12 expression vectors (empty vector, Ras fusion, RAR2K fusion) and baits fused to the Gal4 activation domain (empty vector, Raf, RXR DBD,
PCNA). The b-galactosidase activity resulting from the activation of the LacZ gene hooked to a LexA response element was detected 24 h after retinoic acid
challenge. The Ras/Raf system was used as a positive control. (C) PCNA overexpression inhibits retinoid-induced transcription. HeLa cells were cotransfected in
6-wellscluster( 1.5 · 10
5cells)witharetinoid-induciblereportergenepGL3(RARE)3tkLuc(500ng)designatedasDR5tk-Luchereafter,oratk-drivenluciferase
reporter gene (500 ng, tk-Luc, see Materials and Methods), RARa and RXRa expression vectors (50 ng of each), and a 10-fold stoichiometric excess of a PCNA
expression vector. Twenty-four hours after transfection, cells were challenged, or not, overnight with 1 mM atRA and luciferase activity was assayed. Results are
expressedasthemeanofthreeindependentexperimentsperformedintriplicate.(D)PreventingcoactivatorbindingsiteoccupancydoesnotblockPCNArepressive
effect.HeLacellsweretransfectedasabovewithareportergene,RARaandRXRaexpressionvectors,withorwithoutPCNA(1mg)andincreasingamounts(0.25,
0.5 and 1 mg ) of an expression vector coding for the NR box of DRIP205 (LXXLL) or its mutated inactive version (LXXAA). Luciferase activity was assayed as
described above.
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Reinberg and co-workers (36) demonstrate that the endogen-
ous RARb2 promoter is constitutively associated to RXR/
RAR heterodimers, the Mediator complex and RNA poly-
merase II. Taken collectively, these data suggest that PCNA
is recruited to promoter-bound heterodimers in a ligand-
dependent manner, on both chimeric, unchromatinized and
endogenous, chromatinized DNA templates. This interaction
did not turned out to be cell-speciﬁc, since it was detected in
several cell types (HeLa, MCF7 and P19 cells).
PCNAlevelaffectstheactivityofRA-regulatedchimeric
and endogenous promoters
Full-length PCNA was overepressed in HeLa cells together
with RARa and RXRa. The transcriptional activity of the
RXR/RAR heterodimer was monitored by assaying the luci-
ferase activity from a synthetic RA-responsive reporter gene
(Figure 3A, DR5tk-Luc). In control conditions, atRA induced
a 3.5-fold activation of the reporter gene activity, whereas in
the presence of overexpressed PCNA, the basal activity of the
reporter gene was decreased. However, the inducibility of the
promoter by atRA was not signiﬁcantly altered. This repres-
sion did not result from decreased steady-state levels in RARa
(Figure 3A, lower panel). Interestingly, PCNA overexpression
resulted in the presence of an additional PCNA form, which
migrated more slowly during SDS–PAGE. PCNA was thus
immunoprecipitated with an anti-PCNA antibody and probed
by western blotting using an anti-acetylated lysine antibody.
These experiments revealed that this slowly migrating species
resulted from hyperacetylation of PCNA (Figure 3B), a post-
translational modiﬁcation that targets PCNA to the chromatin,
nuclear matrix and nucleoplasm (37).
We next explored the effect of PCNA depletion in HeLa
cells. HeLa cells were treated with equal amounts of control
small interfering RNA (siRNA) or anti-PCNA siRNA, and the
transcriptional activity of RXRa/RARa heterodimers was
assayed 3 days after siRNA treatment (Figure 3C) As
shown in Figure 3C and D (lower panels), PCNA expression
level was decreased by 50% in these conditions, whereas
RARa and actin levels were not affected. Knocking down
PCNA expression resulted in a strong increase of the overall
transcriptional activity of the reporter gene, showing an
increased basal level and an increased sensitivity to atRA
(4-fold versus 7.5-fold induction). We next assessed the tran-
scriptional activity of endogenously expressed RARa in
response to PCNA knockdown (Figure 3D). MCF7 cells
were transfected as above, using a more sensitive reporter
Figure 2. PCNA interacts with RARa in intact cells and in vitro.( A) PCNA coimmunoprecipitates with RARa in HeLa cells. HeLa cells were transfected with a
RARa expression vector and total extracts were immunoprecipitated with Sepharose-conjugated anti-RAR or PCNA antibodies (or mouse IgG as a control),
respectively, after retinoid challenge. Immune complexes were analyzed by western blots for the presence of RARa and PCNA. (B) PCNA coimmunoprecipitates
with RARa in MCF7 cells. MCF7 total extracts were immunoprecipitated and analyzed as above. (C) The RXR–RAR heterodimer interacts with PCNA in vitro.
RXR and/or RAR were labeled by in vitro translation and incubated with a Glutathione–Sepharose matrix coupled to either GST–PCNA or the receptor interacting
domainofSRC1fusedtoGSTorGSTalone.Whenindicated,aDR5RAREwasaddedtothebindingmixture.Receptorsinteractingwiththematrixwerevisualized
by autoradiography. (D) PCNA associates with a retinoid-induced promoter in intact cells. HeLa cells were cotransfected with PCNA, RXR and RAR expression
vectorstogetherwithDR5tk-Lucretinoid-induciblereportergene.AChIPassaywascarriedoutwithamouseIgG(control),ananti-RARa,ananti-SRC1orananti-
PCNAantibody.TheprecipitatedDNAwasamplifiedbyPCRandanalyzedonanagarosegel.NaiveP19cellswereusedforasimilarassaytoquantifytheamountof
endogenous RARb2 promoter DNA associated to PCNA.
Nucleic Acids Research, 2005, Vol. 33, No. 13 4315Figure 3. The level of expression of PCNA affects transcriptional activation by RARa.( A) HeLa cells were transfected with a retinoid-inducible reporter gene,
RARa,RXRa,and/orPCNAexpressionvectors.Theluciferaseactivitywasassayedaftertreatmentwith1mMatRAovernight.RARa,PCNAandactinlevelswere
assayedbywesternblot(lowerpanel).(B)OverexpressedPCNAishyperacetylated.HeLacellsweretransfectedeitherwithanexpressionvectorcodingforPCNAor
chloramphenicol acetyltransferase as a control. Forty-eight hours later, nuclear extracts were prepared and incubated with a mouse IgG (control) or with an anti-
PCNA antibody.Immunecomplexes were immunoprecipitatedwith proteinG–Sepharosebeads andanalyzed by western blot usingan anti-PCNAantibody(upper
panel) or an anti-acetylated lysine antibody.The left panel correspondsto one tenth of the input in the immunoprecipitationassay. (C) PCNAknockdown increases
atRA responsiveness in HeLa cells. HeLa cells were transfected with a retinoid-inducible reporter gene, RARa and RXRa expression vector after a 24 h treatment
withanti-PCNAsiRNAorcontrolsiRNA.atRAtreatmentandluciferaseassayswereasin(A).(D)PCNAknockdownincreasesatRAresponsivenessinthepresence
of physiological levels of hRARa. MCF7 cells were treated with control or anti-PCNA siRNA and transfected with a retinoid-inducible reporter gene, p800-tkLuc
(seeMaterialsandMethods).atRAresponsivenessofthesystemwasmonitoredasabove.(E)EffectofPCNAconcentrationonatRAresponsivenessofendogenous
genes. HeLa cells were treated as above with control or anti-PCNA siRNA, and mRNA levels were assessed by semi-quantitative RT–PCR after an overnight
challenge with 1 mM atRA (RNAs). A representative experiment is shown; similar results were obtained twice in independent experiments. PCNA and actin levels
were assayed by western blot (proteins).
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(p800 tk Luc) and omitting the RARa expression vector
(Figure 3D). Note that this reporter gene (which contains a
single DR5 RARE) behaved in all instances similar to the
DR5tk-Luc reporter gene (which contains three repeats of a
DR5 RARE) with respect to PCNA overexpression (data not
shown). As shown by western blot analysis (Figure 3D, lower
panel), the level of expression of RARa in MCF7 cells was
lower than in transfected HeLa cells. In conditions for which
PCNA was signiﬁcantly down-regulated, we noted again that
the basal activity of the reporter gene was increased, and that
atRA responsiveness was much improved when compared
with cells harboring unaltered PCNA levels [5.5-fold versus
12-fold (Figure 3D)].
An analogous strategy was followed to assess the effect of
PCNA down-regulation on the activity of atRA-sensitive
endogenousgenes.TheRARa1,RARa2,RARb2.andCRAB-
PII genes are regulated by DR5 [RARa1&2, RARb2 (38–40)],
DR2 and DR1 types RAREs [CRABPII (41)]. In HeLa cells,
RARa1 and RARb2 promoters were not sensitive to atRA.
CRABPII was weakly inducible by this ligand in HeLa cells.
RARa2expression was strongly increased inresponsetoatRA
challenge (Figure 3E). PCNA knockdown strongly modiﬁed
the pattern of expression of the RARb2 gene. Indeed, this
promoter gained full atRA responsiveness with no detectable
increase of the basal level of expression. A weak increase of
the CRABPII gene expression was also consistently noticed in
HeLa cells, although this stemmed from an increased basal
level. Thus, our ﬁnding points to an important role of PCNA as
a promoter-speciﬁc repressor of RA-regulated genes.
PCNA interacts physically with the DNA-binding
domain of RARa
We next investigated the domain(s) of PCNA that interacted
directly with RARa by performing GST pull-down experi-
ments, using puriﬁed GST–PCNA or GST–RARa derivatives.
The ability of isolated domains from RARa to interact
with PCNA was ﬁrst assayed (Figure 4A). The RARa
DNA-binding domain (DBD) interacted strongly with
PCNA, whereas the isolated LBD did not display detectable
interaction with PCNA.
Several RARa mutants, truncated either from the N- or the
C-terminus, were also tested for the interaction with full-
length PCNA (Figure 4B). Full-length, wild-type hRARa
and RAR2K interacted in a ligand-independent manner with
PCNA, as well as a mutant deleted from the A and B domains
[(hRARa )AB], excluding a contribution from the N-terminus
of hRARa. Further deletions within the RARa DBD were
introduced to deﬁne more precisely the RAR–PCNA interac-
tion domain (Figure 4B). As predicted from the results shown
above, the deletion of the DBD within the context of the full-
length RAR abolished the interaction with PCNA. A shorter
deletion, removing the ﬁrst zinc ﬁnger involved in direct
DNA–RAR interaction, did not affect PCNA binding. In con-
trast, removing the linker peptide (amino acids 109–123)
between the ﬁrst and second zinc ﬁnger regions severely affec-
ted thisinteraction.Deletionofthe secondzinc ﬁnger, which is
involved in receptor dimerization (42,43), also generated a
RARa mutant with very low binding to PCNA. Since the
linker peptide does not contain any consensus PCNA binding
sequence [QXX(I/L/M)XX(F/Y)(F/Y) (44)], we carried out an
Ala scan on this region. No mutation altered the binding of
RARa to PCNA (data not shown), suggesting that the RAR
interacting domain is a complex structure.
A similar strategy was applied to PCNA (Figure 4C and D).
As expected from previous results, only the N-terminus of
PCNA interacted signiﬁcantly with RARa. A further trunca-
tion of the N-terminus of PCNA showed that RAR interacted
strongly with the 1–61 region of PCNA. Taken together, these
domain mapping experiments show that RAR interacts with
the N-terminus of PCNA through the C-terminal part of the
RARa DBD.
The speciﬁcity of the PCNA–RAR interaction was further
characterized(Figure5).Asitcouldbepredictedfromthehigh
homology of the DBD with RARb and RARg, we found that
PCNA interacted equally well with these two RAR isotypes.
As shownin Figure 2C, the dimerization partner of RAR, RXR
(RXRa in our assay) did not interact with PCNA (Figure 5A).
Two other NRs heterodimerizing with RXR, the vitamin D
receptor (VDR) and PPARg, were unable to engage physical
interactions with PCNA. In agreement with this, the transcrip-
tional activity of RARb and RARg heterodimerized to RXRa
was blunted in the presence of PCNA (Figure 5B), whereas the
transcriptional activity of a DR1-driven reporter gene in the
presence of RXR alone or of a combination of RXRa and
PPARg was not sensitive to PCNA overexpression. Similarly,
a DR3-driven reporter gene was not sensitive to PCNA over-
expression in the presence of RXRa and VDR (Figure 5C).
DISCUSSION
NRs are subjected to a variety of controls that modulate their
transcriptional activity. They interact with CoAs or CoRs in a
ligand-dependent manner, are modiﬁed post-translationally,
mostly by protein kinases and/or degraded through the pro-
teasome pathway. Most of protein–protein interactions known
to affect RAR transcriptional activity occur within the LBD,
and they have been extensively dissected from both a struc-
tural and a mechanistic point of view. This allowed to propose
a very reﬁned picture of ligand-mediated transcriptional
activation of RXR:RAR heterodimers, in which C-terminal
helix 12 (H12) repositioning plays a crucial role to generate
CoR or CoA interaction interfaces. Much less is known on
H12-independent mechanism(s) that may affect RAR activity.
To gainsomeinsight intotheseprocesses, weundertookatwo-
hybrid screen aiming at identifying proteins interacting with
RAR in a AF-2/H12 independent manner. Among several
candidates, including RXR, the obligate dimerization partner
of RAR, we isolated PCNA, originally identiﬁed as a DNA
sliding clamp enabling DNA polymerases to replicate DNA.
However, PCNA functions extend well beyond DNA replica-
tion, and it participates through multiple protein–protein inter-
action to DNA methylation, chromatin remodeling and cell
cycling (45). Using several approaches, we demonstrate
that (i) PCNA can interact directly with RAR in a ligand-
independent manner in an acellular assay and in yeast,
(ii) PCNA interacts with RAR in intact mammalian cells,
(iii) the PCNA–RAR interaction becomes ligand-dependent
when the interaction takes place within the context of a
DNA-bound RXR–RAR heterodimer in vitro, (iv) this
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regulated promoters in intact cells and (v) this interaction
represses RAR transcriptional activity in a promoter- and
cell type-speciﬁc manner. Our results therefore support a
role for PCNA in regulating RAR transcriptional activity
and hints at a cell cycle-dependent regulation of RAR-
mediated transcription. An yet unresolved issue is why the
RAR–PCNA interaction is ligand-dependent in intact cells.
Our in vitro data suggest that the assembly of RXR–RAR
heterodimers on DNA confers the ligand dependence to this
interaction, alternatively, this may result from a considerably
stabilized RAR–RXR interaction through DNA binding. A
RARa mutant, unable to bind to RAREs, also interacts
with PCNA, albeit in a ligand-independent manner. This
could indicate, although this remains purely speculative,
that RARa engages interaction either with PCNA when
bound to DNA as a heterodimer with RXR, or as a monomer
with DNA-bound PCNA.
Our discovery that PCNA interacts with RARa was unex-
pected, since RARa contains none of the PCNA interaction
motifs, the PIP box [QXX(L/I/M)XX(Y/F)(Y/F)] or the KA
box [(A/L/Q)XX(L/V)]. Moreover, PCNA has been shown to
interact mostly with factors having a low afﬁnity for DNA and
limited DNA sequence speciﬁcity. It is not clear at this point
how PCNA exerts its repressive effect on RAR. We have
observed that in vitro DNA binding of RXR/RAR heterodi-
mers is not affected by increasing concentrations of PCNA
(data not shown), excluding a steric hindrance of RARa DBD
upon PCNA binding. This is further strengthened by the
fact that PCNA is detected on chimeric and endogenous
Figure 4. DomainmappingoftheRARa–PCNAinteraction.(A)TheRARaDBDissufficientforRAR–PCNAinteraction.Full-lengthRARa,ortheisolatedDBD
or LBD fused to GST were incubated with labeled PCNA and incubated with GST alone or GST-RAR bound to Sepharose beads. After extensive washing, bound
material was analyzed by SDS–PAGE and bound PCNA was visualized by autoradiography. (B) GST pull-down assay with full-length PCNA. The indicated RAR
mutantsweretranslatedandlabeledinvitroandincubatedwithaSepharose–glutathione/GST–PCNAslurry.Theinteractionwasanalyzedasin(A).Asimilarassay
was carried out with RXRa.( C) Mapping of the RAR interaction region within PCNA. Various PCNA deletion mutants were labeled and incubated with the full-
length RARa-GST fusion protein. Bound PCNA was analyzed as above. (D) Minimal PCNA–RAR interaction domain. A Sepharose-bound GST fused to amino
acids 1–61 from PCNA was incubated with labeled, full-length RARa. Bound material was assayed as above.
4318 Nucleic Acids Research, 2005, Vol. 33, No. 13retinoid-regulated promoter in intact cells (Figure 2). PCNA
interacts with a wide array of proteins, with diverse biological
activities, including cylin-dependent kinase (cdk)-cyclin E or -
cyclin Dcomplexes.D- andE-typecyclins have been shownto
act as CoA and CoR for several NRs, including RAR (6,46–
51). PCNA also acts by recruiting p300 and inhibiting its
acetyl transferase activity (25,52), thus behaving as a selective
inhibitor of p300-mediated transcription. In light of these
Figure 5. (A) PCNA interacts specifically with RARs. hRARb, hRARg, hRXRa, hVDR and hPPARg receptors were translated and labeled in vitro and incubated
withaSepharose–glutathione/GST–PCNAslurry.Theinteractionwasanalyzedasdescribedin(Figure4A).(B)PCNAoverexpressioninhibitstranscriptioninduced
par RARs isotypes. HeLa cells were cotransfected as described elsewhere in 6-wells cluster ( 1.5 · 10
5 cells) with a retinoid-inducible reporter gene pGL3(RAR-
E)3tkLuc (500 ng), RARb or RARg and RXRa expression vectors (50 ng of each), and a 10-fold stoichiometric excess of a PCNA expression vector. Twenty-four
hours after transfection, cells were challenged, or not, overnight with 1 mM atRA and luciferase activity was assayed. Results are expressed as the mean of three
independent experiments performed in triplicate. (C) RXRa, VDR and PPARg induced transcriptional activities are not sensitive to PCNA overexpression. HeLa
cells were cotransfected as in B) with a DR1-driven or a DR3-driven reporter genes, RXRa and/or VDR or PPARg expression vectors. Twenty-four hours after
transfection, cells were challenged, or not, overnight with 1 mM9 - cis RA, Vit D3 or rosiglitazone, respectively and luciferase activity was assayed.
Nucleic Acids Research, 2005, Vol. 33, No. 13 4319results, it is tempting to speculate that the selective effect of
PCNA expression knockdown on endogenous RARb2 expres-
sion might reﬂect a requirement for p300 for RARb2 promoter
activation. However, this would reﬂect an AF2-dependent
mechanism, and we showed that PCNA interaction is AF2-
independent. Moreover, p300 acetyl transferase activity is
not required for retinoid-induced transcription (53); on the
contrary, pCAF acetyl transferase activity is necessary for
retinoid-induced transcription, and its interaction with the
RAR DBD has been documented (54). An alternative mech-
anism to coactivator displacement could be the tethering of
CoR. Histone desacetylase (HDAC) activity has been shown
to be an integral component of the repressive activity of unlig-
anded RAR, with HDAC1 and HDAC3 interacting indirectly
with RAR through corepressors molecules, such as SMRT and
NCoR. Recently, PCNA has been shown to interact directly
with HDAC1 (55), rising the possibility that RAR-bound
PCNA targets an additional HDAC molecule to further repress
RAR-controlled transcriptional mechanisms. Here, it is worth
noting that these various partners may engage interactions,
which were not detected in our initial screen, and may con-
tribute to establish a ligand dependency to the RAR–PCNA
interaction in intact cells. At this point, these mechanisms
remain purely speculative and additional experiments are
required to fully characterize the PCNA-mediated repression
mechanism. Since PCNA is a cyclin, whose expression is
highly upregulated in S phase (56), it would also be of interest
to identify retinoid-controlled genes, which undergo a cell
cycle-dependent, PCNA-mediated repression.
Besides a ‘simple’ cell cycle-dependent repression of
retinoid-controlled genes, can we envision another role for
RAR–PCNA interaction? PCNA is intimately linked to the
nucleotide excision repair (NER) process through its associ-
ation with XPG (57) and its involvement inDNA resynthesis.
NER can be divided into two types of activities: global gen-
ome repair, which is a slow, non-targeted process, and the
transcription-coupled repair (TCR), which relies on the
targeted recruitment of the NER machinery to elongating
RNA polymerase II [see (58) and references therein]. Some
NER factors participate equally to DNA repair and transcrip-
tion activation: TFIIH, which is part of the NER complex,
binds, phosphorylates and activates RAR in an AF2-
independent manner (20). A role for RAR in TCR has thus
been hypothesized and demonstrated (58), which could be
exerted through chromatin remodeling and/or the recruitment
of DNA repair factors. Here, we provide data suggesting that
PCNA could participate to transcriptional control and DNA
repair in a fashion analogous to that of TFIIH, by interacting
with RAR. It would be of interest to determine the actual role
of RAR in TCR and DNA synthesis, if any.
In summary, our data are consistent with a role of PCNA as
a promoter- and cell-speciﬁc repressor of RAR transcriptional
activity, and suggest, although this remains to be formally
established, that the RAR–PCNA interaction may participate
in coupling transcription to DNA repair.
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